55,824 Shares in Zoetis Inc. $ZTS Acquired by Hohimer Wealth Management LLC

Hohimer Wealth Management LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 55,824 shares of the company’s stock, valued at approximately $4,012,000.

A number of other hedge funds also recently made changes to their positions in ZTS. Prosperity Bancshares Inc purchased a new stake in shares of Zoetis during the 4th quarter valued at $25,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Zoetis in the 1st quarter worth $28,000. Root Financial Partners LLC raised its position in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the period. Elyxium Wealth LLC acquired a new position in Zoetis in the fourth quarter valued at $32,000. Finally, Wellington Grp LLC boosted its holdings in Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after acquiring an additional 267 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ZTS shares. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Zacks Research lowered Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. HSBC reduced their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. JPMorgan Chase & Co. dropped their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Finally, William Blair restated a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $109.62.

Zoetis Stock Down 2.9%

Shares of Zoetis stock opened at $73.64 on Friday. Zoetis Inc. has a twelve month low of $71.45 and a twelve month high of $160.48. The stock has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a price-to-earnings-growth ratio of 1.31 and a beta of 0.74. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a fifty day moving average price of $76.30 and a 200 day moving average price of $99.01.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm’s revenue was down .2% compared to the same quarter last year. During the same period last year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s dividend payout ratio (DPR) is 34.93%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.